We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+9.53%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.36B
AUM Growth
+$77.6M
Cap. Flow
+$46.1M
Cap. Flow %
3.39%
Top 10 Hldgs %
13.88%
Holding
1,633
New
514
Increased
325
Reduced
386
Closed
373

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$14.2M
2
DOMO icon
Domo
DOMO
+$12.7M
3
NFLX icon
Netflix
NFLX
+$12.4M
4
EA
Electronic Arts
EA
+$12.3M
5
DAY
Dayforce
DAY
+$11.5M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$17.1M
2
COOP
Mr. Cooper
COOP
+$13.5M
3
K
Kellanova
K
+$11.9M
4
LITE icon
Lumentum
LITE
+$9.69M
5
IBIT icon
iShares Bitcoin Trust
IBIT
+$9.44M

Sector Composition

Rank Sector Weight
1 Technology 23.27%
2 Healthcare 13.54%
3 Communication Services 10.55%
4 Consumer Discretionary 9.61%
5 Industrials 9.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BBAI icon
1301
BigBear.ai
BBAI
$1.55B
-24,514
Closed -$160K
BBWI icon
1302
Bath & Body Works
BBWI
$3.89B
-15,087
Closed -$389K
BBY icon
1303
Best Buy
BBY
$17.4B
-4,719
Closed -$357K
BEKE icon
1304
KE Holdings
BEKE
$19.5B
-11,965
Closed -$227K
KEEL
1305
Keel Infrastructure Corp
KEEL
$2.05B
-150,000
Closed -$423K
BJRI icon
1306
BJ's Restaurants
BJRI
$1.46B
-6,722
Closed -$205K
BKLN icon
1307
Invesco Senior Loan ETF
BKLN
$6.74B
-80,340
Closed -$1.68M
BMRN icon
1308
BioMarin Pharmaceuticals
BMRN
$13.3B
-5,317
Closed -$288K
BND icon
1309
Vanguard Total Bond Market
BND
$161B
-4,550
Closed -$338K
BNDX icon
1310
Vanguard Total International Bond ETF
BNDX
$82.8B
-5,450
Closed -$270K
BOX icon
1311
Box
BOX
$4.65B
-6,523
Closed -$210K
BRY
1312
DELISTED
Berry Corp
BRY
-15,411
Closed -$58.3K
BTI icon
1313
British American Tobacco
BTI
$123B
-4,883
Closed -$259K
BVN icon
1314
Compañía de Minas Buenaventura
BVN
$8.78B
-9,000
Closed -$219K
BWX icon
1315
State Street SPDR Bloomberg International Treasury Bond ETF
BWX
$1.31B
-73,150
Closed -$1.68M
CAL icon
1316
Caleres
CAL
$486M
-12,917
Closed -$168K
CART icon
1317
Maplebear
CART
$11.9B
-22,219
Closed -$817K
CCI icon
1318
Crown Castle
CCI
$31.3B
-24,815
Closed -$2.39M
CCRD
1319
DELISTED
CoreCard
CCRD
-17,684
Closed -$476K
CDNS icon
1320
Cadence Design Systems
CDNS
$91.4B
-661
Closed -$232K
CFSB
1321
DELISTED
CFSB Bancorp
CFSB
-46,773
Closed -$664K
CGAU
1322
Centerra Gold
CGAU
$4.17B
-22,522
Closed -$242K
CGEM icon
1323
Cullinan Oncology
CGEM
$1.18B
-48,652
Closed -$289K
CHRW icon
1324
C.H. Robinson
CHRW
$17.3B
-1,545
Closed -$205K
CIB icon
1325
Grupo Cibest SA
CIB
$21.7B
-4,000
Closed -$208K

Similar funds

Prelude Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prelude Capital Management held 1,633 positions worth $1.36B, up 6.1% from $1.28B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Prelude Capital Management deployed $46.1M of net new capital in Q4 2025, opening 514 new positions and adding to 325 existing holdings. Its largest new stake was Nice: 117,600 shares worth $13.3M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Lumentum, an estimated $9.69M trimmed.

  • Prelude Capital Management's largest Q4 2025 buy was Nice: 117,600 shares worth $13.3M.
  • Prelude Capital Management added most to Domo in Q4 2025, an estimated $12.7M increase.
  • Prelude Capital Management's biggest Q4 2025 reduction was Lumentum, cutting an estimated $9.69M.
  • Prelude Capital Management fully exited Verona Pharma in Q4 2025, selling an estimated $17.1M.
  • Prelude Capital Management's ten largest holdings make up 14% of its $1.36B portfolio in Q4 2025.
  • Prelude Capital Management opened 514 new positions and closed 373 in Q4 2025.
  • Prelude Capital Management's portfolio value rose 6.1% quarter-over-quarter to $1.36B.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.